Objective: The GIANT study collected information on patients with acute exacerbations of chronic bronchitis (AECB) and chronic obstructive pulmonary disease (COPD) and the effect of treatment with moxifloxacin.
Methods: AECB history, concomitant diseases, moxifloxacin treatment, concomitant medication, clinical symptoms and adverse events were recorded. A questionnaire at the end of treatment recorded the impact on patients’ daily lives.
Results: Among 9225 patients from eight European countries, marked variation was seen in characteristics including age, smoking history and type of exacerbation. Spirometry use was more common among chest physicians (66.7%) than GPs (15.5%). Patients with Anthonisen type 1 and 2 exacerbations had more frequent exacerbations and these patients experienced a greater impact on daily activities compared with patients with type 3 episodes. Patient symptoms improved with moxifloxacin treatment after a mean (SD) of 3.4 (1.8) days, allowing return to normal daily activities after 5.4 (4.4) days and with full recovery taking 6.5 (3.1) days.
Conclusions: Characteristics of patients with AECB and acute exacerbations of COPD differ among European countries. Spirometry is under-used, particularly in primary care and antibiotic treatment does not always follow current guidelines. Results confirm the efficacy of moxifloxacin in the treatment of AECB in real-life conditions.
Adams, S.G., Anzueto, A., Pugh, J.A., Lee, S. and Hazuda, H.P. ( 2006) Mexican American elders have similar severities of COPD despite less tobacco exposure than EuropeanAmerican elders. Respir Med100: 1966-1972.
2.
Anthonisen, N.R., Manfreda, J., Warren, C.P., Hershfield, E.S., Harding, G.K. and Nelson, N.A. ( 1987) Antibiotic therapy in exacerbations of chronic pulmonary disease. Ann Intern Med106: 196-204.
3.
Anzueto, A. ( 2006) Impact of exacerbations in patients with COPD. Hot Topics Respir Dis2: 7-13.
4.
Black, N. ( 1996) Why we need observational studies to evaluate the effectiveness of health care. BMJ312: 1215-1218.
5.
Buist, A.S., McBurnie, M.A., Vollmer, W.M., Gillespie, S., Burney, P., Mannino, D.M. et al. (2007) for the BOLD Collaborative Research Group.International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet370: 741-750.
6.
Chapman, K.R., Mannino, D.M., Soriano, J.B. et al. (2006) Epidemiology and costs of chronic obstructive pulmonary disease. Eur Respir J27: 188-207.
7.
Derom, E., van Weel, C., Liistro, G., Buffels, J., Schermer, T., Lammers, E. et al. (2008) Primary care spirometry. Eur Respir J31: 197-203.
8.
Donaldson, G.C., Seemungal, T.A., Bhowmik, A. and Wedzicha, J.A. ( 2002) Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax57: 847-852.
9.
Garcia-Aymerich, J., Lange, P., Benet, M., Schnohr, P. and Antó, J.M. ( 2006) Regular physical activity reduces hospital admission and mortality in chronic obstructive pulmonary disease: a population based cohort study. Thorax61: 772-778.
10.
Halpin, D.M. and Miravitlles, M. ( 2006) Chronic obstructive pulmonary disease: the disease and its burden to society. Proc Am Thorac Soc3: 619-623.
11.
Hannan, E.L. ( 2008) Randomized clinical trials and observational studies. Guidelines for assessing respective strengths and limitations. J Am Coll Cardiovasc Interv1: 211-217.
12.
Kessler, R., Stahl, E., Vogelmeier, C., Haughney, J., Trudeau, E., Löfdahl, C.G. et al. (2006) Patient understanding, detection, and experience of COPD exacerbations: an observational, interview-based study. CHEST130: 133-142.
13.
Koch, H., Landen, H. and Stauch, K. ( 2004) Daily-practice treatment of acute exacerbations of chronic bronchitis with moxifloxacin in a large cohort in Germany. Clin Drug Investig24: 449-455.
14.
Landen, H., Möller, M., Tillotson, G.S., Kubin, R. and Höffken, G. ( 2001) Clinical experience in Germany of treating community-acquired respiratory infections with the new 8-methoxyfluoroquinolone, moxifloxacin . J Int Med Res29: 51-60.
15.
Llor, C., Molina, J., Naberan, K., Cots, J.M., Ros, F. and Miravitlles, M.EVOCA study group. (2008) Exacerbations worsen the quality of life of chronic obstructive pulmonary disease patients in primary healthcare. Int J Clin Pract62: 585-592.
16.
Miravitlles, M. ( 2007a) Moxifloxacin in the management of exacerbations of chronic bronchitis and COPD. Int J Chron Obstruct Pulmon Dis2: 191-204.
17.
Miravitlles, M. ( 2007b) Do we need new antibiotics for treating exacerbations of COPD? Ther Adv Respir Dis1: 61-76.
18.
Miravitlles, M. and Llor, C. ( 2007) Determining factors in the prescription of, moxifloxacin , in exacerbations of chronic bronchitis in the primary care setting. Clin Drug Investig27: 95-104.
19.
Miravitlles, M., Anzueto, A., Legnani, D., Forstmeier, L. and Fargel, M. ( 2007) Patient’s perception of exacerbations of COPD - the PERCEIVE study. Respir Med101: 453-460.
20.
Miravitlles, M., de la Roza, C., Naberan, K., Lamban, M., Gobartt, E. and Martin, A. ( 2007d) Use of spirometry and patterns of prescribing in COPD in primary care. Respir Med101: 1753-1760.
21.
Miravitlles, M., Ferrer, M., Pont, A., Zalacain, R., Alvarez-Sala, J.L., Masa, F. et al. (2004) Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study. Thorax59: 387-395.
22.
Miravitlles, M., Guerrero, T., Mayordomo, C., Sánchez-Agudo, L., Nicolau, F. and Segú, J.L. ( 2000) Factors associated with increased risk of exacerbation and hospital admission in a cohort of ambulatory COPD patients: a multiple logistic regression analysis. The EOLO Study Group. Respiration67: 495-501.
23.
Miravitlles, M., Llor, C., Naberan, K., Cots, J.M. and Molina, J., for the EFEMAP study group. (2005 ) Variables associated with recovery from acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease. Respir Med99: 955-965.
24.
Miravitlles, M., Molina, J. and Brosa, M. ( 2007c) Clinical efficacy of moxifloxacin in the treatment of exacerbations of chronic bronchitis: a systematic review and meta-analysis . Arch Bronconeumol43: 22-28.
25.
Miravitlles, M., Monsó, E., Mensa, J., Aquarón Pérez, J. , Barberán, J. and Bárcena Caamaño, M. (2008a) Antimicrobial treatment of exacerbation in chronic obstructive pulmonary disease: 2007 consensus statement. Arch Bronconeumol44: 100-108.
26.
Miravitlles, M., Murio, C., Tirado-Conde, G., Levy, G., Muellerova, H., Soriano, J.B. et al. (2008b) Geographic differences in clinical characteristics and management of COPD: the EPOCA study. Int J Chron Obstruct Pulmon Dis3: 803-814.
27.
Miravitlles, M., Zalacain, R., Murio, C., Ferrer, M., Alvarez-Sala, J.L., Masa, J.F. et al., on behalf of the IMPAC Study Group. ( 2003) Speed of recovery from acute exacerbations of chronic obstructive pulmonary disease after treatment with antimicrobials: results of a two-year study. Clin Drug Investig23: 439-450.
28.
Niederman, M.S., Anzueto, A., Sethi, S., Choudhri, S., Kureishi, A., Haverstock, D. et al. (2006) Eradication of H. influenzae in AECB: A pooled analysis of moxifloxacin phase III trials compared with macrolide agents. Respir Med100: 1781-1790.
29.
Niewoehner, D.E., Collins, D. and Erbland, M.L. ( 2000) Relation of FEV(1) to clinical outcomes during exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. Am J Respir Crit Care Med161: 1201-1205.
30.
Pitta, F., Troosters, T., Spruit, M.A., Probst, V.S., Decramer, M. and Gosselink, R. ( 2005) Characteristics of physical activities in daily life in chronic obstructive pulmonary disease. Am J Respir Crit Care Med171: 972-977.
31.
Rabe, K.F., Hurd, S., Anzueto, A., Barnes, P.J., Buist, S.A., Calverley, P. et al. (2007) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary . Am J Respir Crit Care Med176: 532-555.
32.
Seemungal, T.A.R., Donaldson, G.C., Paul, E.A., Bestall, J.C., Jeffries, D.J. and Wedzicha, J.A. ( 1998) Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med157: 1418-1422.
33.
Sobradillo Peña, V., Miravitlles, M., Gabriel, R., Jiménez-Ruiz, C.A., Villasante, C., Masa, J.F. et al. (2000) Geographical variations in prevalence and underdiagnosis of COPD.Results of the IBERPOC multicentre epidemiological study. CHEST118: 981-989.
34.
Soler-Cataluña, J.J., Martínez-García, M.A., Román Sánchez, P., Salcedo, E., Navarro, M. and Ochando, R. (2005) Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax60: 925-931.
35.
Soriano, J.B. ( 2007) Epidemiology of chronic obstructive pulmonary disease worldwide. Hot Topics Respir Dis3: 13-18.
36.
Wilson, R., Allegra, L., Huchon, G., Izquierdo, J.L., Jones, P., Schaberg, T. et al. (2004) for the MOSAIC Study Group. (2004) Short-term and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis. CHEST125: 953-964.
37.
Wilson, R., Jones, P., Schaberg, T., Arvis, P., Duprat-Lomon, I. and Sagnier, P.P. ( 2006) Antibiotic treatment and factors influencing short and long-term outcomes of acute exacerbations of chronic bronchitis. Thorax61: 337-342.
38.
Woodhead, M., Blasi, F., Ewig, S., Huchon, G., Ieven, M., Ortqvist, A. et al. for the European Respiratory Society, European Society of Clinical Microbiology and Infectious Diseases. ( 2005) Guidelines for the management of adult lower respiratory tract infections. Eur Respir J26: 1138-1180.
39.
Yu, C.Y.(2009) Observational studies: a review of study designs, challenges and strategies to reduce confounding. Int J Clin Pract63: 691-697.
